Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
From BioCentury This Week · · 33 min
This plays from the publisher's own server. We do not host a copy.
Description
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss (https://www.biocentury.com/article/658795) how the company has built a pipeline and set of enabling technologies that could enable a steep period of value creation based on RNAi. The team then analyzes the $2 billion deal (https://www.biocentury.com/article/658874) between Synnovation and Novartis for a pan-mutant-selective PI3Kα inhibitor. The analysts also assess where AI is integrating (https://www.biocentury.com/article/658565) into the biotech venture funnel and provide insights into ultra-rare disease advocacy (https://www.biocentury.com/article/658855), FDA’s search for a successor to CBER Director Vinay Prasad, and the Trump administration’s most-favored nation (MFN) drug pricing policy.
View full story: https://www.biocentury.com/article/658892
#RNAiTherapeutics #BiotechMA #PI3KAlpha #AIDrugDiscovery #DrugPricingPolicy
00:00 - Introduction 01:14 - Bio€quity Europe 05:33 - Arrowhead 16:49 - Synnovation Novartis 20:00 - AI in Biotech Venture 27:07 - Rare Disease Advocacy 31:22 - MFN Pricing Policy
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)